Michael Hayden, MD PhD | CMHF
New Teva CEO shakes up structure and executive ranks as major layoffs loom | Fierce Pharma
Teva R&D Strategy
Michael Hayden - Director at n-Lorem Foundation | The Org
Prilenia Therapeutics raises $62.5m, names Michael Hayden CEO - Globes
Axovant poaches Allergan's and Teva's chief medical and science officers - PMLiVE
How One of the World's Leading Geneticists Recovered His Family's Stolen Legacy - Tablet Magazine
How One of the World's Leading Geneticists Recovered His Family's Stolen Legacy - Tablet Magazine
Chutes & Ladders—Teva rejigs C-suite amid major restructuring | Fierce Biotech
Teva and Microchips : Partnership through Digital Drug Delivery Technology. Opening of Teva R&D Center in Croatia - Israël Science Info
Celebrating Biopharma Innovation: The Top 10 | Reuters Events | Pharma
New Teva CEO shakes up structure and leadership at troubled drugmaker | The Times of Israel
VIP Reception
Michael Hayden, MD PhD | CMHF
Michael HAYDEN | MBCHb PhD | University of British Columbia - Vancouver, Vancouver | UBC | Department of Medical Genetics
Senior Advisors copy — Biolojic
Michael Hayden Net Worth (2022) | wallmine
Podcast Transcript Michael Hayden and PROOF-HD v.1 08Jan2021
Dr. Michael Hayden MBChB , PhD - Chief Executive Officer - Prilenia | LinkedIn
Michael Hayden, MD, PhD - World Neuroscience Innovation Forum
Huntington's drug sprung from Teva's lab moves forward with $62.5M VC backing | S&P Global Market Intelligence
At Risk for Huntington's Disease: 'Darkness replaced by hope and light': taking stock of Huntington's disease research
Teva appoints genetics specialist as its first president of global R&D - PMLiVE
Teva Pharmaceutical Industries Ltd. - At the opening of a new scientific research center in the Galilee region of Israel (pictured, left to right): Erez Vigodman, Teva President and CEO; Prof. Ran
